Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas

1. A method for the treatment of human merkel cell carcinoma, gastric neuroendocrine carcinoma, or small cell lung cancer comprising the administration to a patient in need thereof an effective amount of a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof,

wherein,

W is N, C—H, or C—F;

X is hydrogen, halogen, —CN, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted carbocyclylalkynyl, optionally substituted aryl, or optionally substituted heteroaryl;

Y is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl;

Z is an optionally substituted group chosen from alkyl, carbocyclyl, C-attached heterocyclyl, N-attached heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, —O-heterocyclyl, —N(R)-heterocyclyl, —O-heterocyclylalkyl, —N(R)-heterocyclylalkyl, —N(R)(C 1 -C 4 alkylene)-NR 2 , —O(C 1 -C 4 alkylene)-NR 2 ; and

R is hydrogen or C 1 -C 4 alkyl.

2. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W is C—H.

3. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W is C—F.

4. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of hydrogen, halogen, optionally substituted alkyne, optionally substituted carbocyclylalkynyl, optionally substituted aryl, and optionally substituted heteroaryl.

5. The method of claim 4 , or a pharmaceutically acceptable salt thereof, wherein X is optionally substituted aryl.

6. The method of claim 5 , or a pharmaceutically acceptable salt thereof, wherein the optionally substituted aryl is an optionally substituted phenyl.

7. The method of claim 4 , or a pharmaceutically acceptable salt thereof, wherein X is an optionally substituted heteroaryl.

8. The method of claim 7 , or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of optionally substituted pyridinyl, optionally substituted pyrazolyl, and optionally substituted indazolyl.

9. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is heterocyclylalkyl selected from the group consisting of optionally substituted —O-heterocyclylalkyl, optionally substituted —N(H)-heterocyclylalkyl, and optionally substituted —N(Me)-heterocyclylalkyl.

10. The method of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said heterocyclylalkyl group has the formula R c -heterocyclyl in which R c is an optionally substituted C 1 -C 3 alkylene chain or an optionally substituted C 1 alkylene chain.

11. The method of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said heterocyclylalkyl group has the formula R c -heterocyclyl in which heterocyclyl is an optionally substituted nitrogen-containing 4-, 5-, 6-, or 7-membered heterocyclyl.

12. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is an optionally substituted N-attached heterocyclyl.

13. The method of claim 12 , or a pharmaceutically acceptable salt thereof, wherein said optionally substituted N-attached heterocyclyl is 4-, 5-, 6-, or 7-membered N-attached heterocyclyl.

14. The method of claim 13 , or a pharmaceutically acceptable salt thereof, wherein said optionally substituted N-attached heterocyclyl is 6-membered N-attached heterocyclyl.

15. The method of claim 12 , or a pharmaceutically acceptable salt thereof, wherein said optionally substituted N-attached heterocyclyl is an optionally substituted piperidine.

16. The method of claim 15 , or a pharmaceutically acceptable salt thereof, wherein the optionally substituted piperidine is 4-aminopiperidine.

17. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is an optionally substituted alkyl selected from the group consisting of optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 alkyl, and methyl group.